Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
05 03 2019
Historique:
entrez: 6 3 2019
pubmed: 6 3 2019
medline: 15 3 2019
Statut: ppublish

Résumé

Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown. To examine the effect of 2 nutritional strategies (multinutrient supplementation, food-related behavioral activation therapy) and their combination for prevention of a new MDD episode in overweight adults with subsyndromal depressive symptoms. This multicenter 2 × 2 factorial randomized clinical trial included overweight adults (body mass index, 25-40) with elevated depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] scores ≥5) and no MDD episode in the past 6 months from 4 European countries. A total of 1025 adults were randomized (July 30, 2015-October 12, 2016) and followed up for 1 year (October 13, 2017). Daily multinutrient supplements (1412-mg omega-3 fatty acids, 30-μg selenium, 400-μg folic acid, and 20-μg vitamin D3 plus 100-mg calcium) vs placebo and 21 individual or group therapy sessions vs none (blinded to researchers) for 1 year. Participants were allocated to placebo without therapy (n = 257), placebo with therapy (n = 256), supplements without therapy (n = 256), and supplements with therapy (n = 256). Cumulative 1-year onset of MDD via the Mini International Neuropsychiatric Interview at 3, 6, and 12 months. Logistic regression using effect-coded variables (-1 indicating control, 1 indicating intervention) evaluated intervention effects both individually and in combination (interaction) on MDD onset. Among 1025 participants (mean age, 46.5 years; 772 women [75%]; mean BMI, 31.4), 779 (76%) completed the trial. During the 12-month follow-up, 105 (10%) developed MDD: 25 (9.7%) patients in the placebo without therapy, 26 (10.2%) in the placebo with therapy, 32 (12.5%) in the supplement without therapy, and 22 (8.6%) in the supplement with therapy group. None of the treatment strategies affected MDD onset. The odds ratio (OR) for supplements was 1.06 (95% CI, 0.87-1.29); for therapy, 0.93 (95% CI, 0.76-1.13); and for their combination, 0.93 (95% CI, 0.76-1.14; P for interaction, .48). One person in the supplementation with therapy group, died. Twenty-four patients in each of the placebo groups and 24 patients in the supplementation with therapy group were hospitalized, and 26 patients in the supplementation-only group were hospitalized. Among overweight or obese adults with subsyndromal depressive symptoms, multinutrient supplementation compared with placebo and food-related behavioral activation therapy compared with no therapy did not reduce episodes of major depressive disorder during 1 year. These findings do not support the use of these interventions for prevention of major depressive disorder. ClinicalTrials.gov Identifier: NCT02529423.

Identifiants

pubmed: 30835307
pii: 2726983
doi: 10.1001/jama.2019.0556
pmc: PMC6439597
doi:

Banques de données

ClinicalTrials.gov
['NCT02529423']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

858-868

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Psychol Med. 1996 May;26(3):477-86
pubmed: 8733206
Contemp Clin Trials Commun. 2018 Mar 28;10:80-85
pubmed: 29696162
Am J Psychiatry. 2008 Oct;165(10):1272-80
pubmed: 18765483
J Clin Psychiatry. 2008 Aug;69(8):1203-9
pubmed: 18557664
Eur J Clin Nutr. 2011 Jun;65(6):750-6
pubmed: 21427744
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Transl Psychiatry. 2016 Mar 15;6:e756
pubmed: 26978738
BMC Med. 2017 Jan 30;15(1):23
pubmed: 28137247
Br J Psychiatry. 2015 Apr;206(4):324-31
pubmed: 25573400
Annu Rev Public Health. 2008;29:115-29
pubmed: 18348707
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Res Publ Assoc Res Nerv Ment Dis. 1983;60:115-20
pubmed: 6823524
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Prev Med. 2015 Jul;76 Suppl:S22-32
pubmed: 25445331
Public Health Nutr. 2015 Aug;18(11):2074-93
pubmed: 25465596
Am J Psychiatry. 2016 Jun 1;173(6):575-87
pubmed: 27113121
Stat Methods Med Res. 2010 Jun;19(3):237-70
pubmed: 19608601
JAMA. 2012 Mar 14;307(10):1033-4
pubmed: 22416097
J Nutr. 2004 Sep;134(9):2372-80
pubmed: 15333731
J Affect Disord. 2016 Jul 1;198:1-14
pubmed: 26998791
Mol Psychiatry. 2014 Apr;19(4):444-51
pubmed: 23568194
Mol Psychiatry. 2019 Jan;24(1):18-33
pubmed: 29453413
Int J Epidemiol. 2014 Apr;43(2):318-29
pubmed: 24760873
Nutr Neurosci. 2019 Jul;22(7):474-487
pubmed: 29215971
Br J Nutr. 2008 Feb;99(2):421-31
pubmed: 17956647
Biol Psychiatry. 2006 Jan 15;59(2):147-54
pubmed: 16181615
J Clin Epidemiol. 2003 Dec;56(12):1163-9
pubmed: 14680666
Am J Prev Med. 2014 Oct;47(4):498-504
pubmed: 25092122
PLoS One. 2014 Jun 17;9(6):e100100
pubmed: 24936656
Arch Gen Psychiatry. 2009 Mar;66(3):297-304
pubmed: 19255379
JAMA. 2016 May 3;315(17):1854-63
pubmed: 27139058
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
BMC Psychiatry. 2016 Jun 08;16:192
pubmed: 27277946
J Psychiatr Res. 2018 Feb;97:38-46
pubmed: 29175296
J Affect Disord. 2018 Jan 15;226:346-354
pubmed: 29031185

Auteurs

Mariska Bot (M)

Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health research institute, GGZ inGeest Specialized Mental Health Care, Amsterdam, the Netherlands.

Ingeborg A Brouwer (IA)

Department of Health Sciences, Faculty of Science and Amsterdam Public Health research institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Miquel Roca (M)

Institut Universitari d' Investigació en Ciències de la Salut, Idisba, Rediapp, University of Balearic Islands, Palma de Mallorca, Spain.

Elisabeth Kohls (E)

Department of Psychiatry and Psychotherapy, University Leipzig, Medical Faculty, Leipzig, Germany.

Brenda W J H Penninx (BWJH)

Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health research institute, GGZ inGeest Specialized Mental Health Care, Amsterdam, the Netherlands.

Ed Watkins (E)

Department of Psychology, University of Exeter, Exeter, United Kingdom.

Gerard van Grootheest (G)

Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health research institute, GGZ inGeest Specialized Mental Health Care, Amsterdam, the Netherlands.

Mieke Cabout (M)

Department of Health Sciences, Faculty of Science and Amsterdam Public Health research institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Ulrich Hegerl (U)

Department of Psychiatry and Psychotherapy, University Leipzig, Medical Faculty, Leipzig, Germany.

Margalida Gili (M)

Institut Universitari d' Investigació en Ciències de la Salut, Idisba, Rediapp, University of Balearic Islands, Palma de Mallorca, Spain.

Matthew Owens (M)

Department of Psychology, University of Exeter, Exeter, United Kingdom.

Marjolein Visser (M)

Department of Health Sciences, Faculty of Science and Amsterdam Public Health research institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH